Investigators calculated that the new assay, which includes 67 SNPs, could offer a 50 percent improvement over previous methods if used in newborn screening.
The company aims to launch the test, which it believes will improve monitoring and treatment of patients with diabetes, in China within the next two years.
The firm plans to seek full commercial approval for its assay, which integrates biomarker identification with a patient's electronic medical record, later this year.
LabCorp and TACHC will use data analytics and clinical decision support tools to improve the care of patients with chronic kidney disease and diabetes.
Becton Dickinson got clearance for a platform and test for the rapid identification and determination of antimicrobial susceptibility of gram-negative bacteria.
